Journal of Research in Ayurvedic Sciences

Register      Login

VOLUME 1 , ISSUE 1 ( January-March, 2017 ) > List of Articles

RESEARCH ARTICLE

Clinical Efficacy and Safety of Ashokarishta, Ashvagandha Churna and Pravala Pishti in the Management of Menopausal Syndrome: A Prospective Open-label Multicenter Study

Rinku Tomar, Indira Kumari, Vilas Gangurde, MM Padhi

Citation Information : Tomar R, Kumari I, Gangurde V, Padhi M. Clinical Efficacy and Safety of Ashokarishta, Ashvagandha Churna and Pravala Pishti in the Management of Menopausal Syndrome: A Prospective Open-label Multicenter Study. J Res Ayurvedic Sci 2017; 1 (1):9-16.

DOI: 10.5005/jp-journals-10064-0002

License: CC BY 3.0

Published Online: 00-03-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction

The menopausal period comprises about one-third of average women's life. During this period, women are vulnerable to conditions caused by estrogen deficiency from short-term discomfort to long-term health problems.

Aim

To evaluate the clinical efficacy of Ashokarishta, Ashvagandha Churna and Pravala Pishti in the management of menopausal syndrome and to evaluate changes in the quality of life in women.

Materials and methods

This trial was a multicenter single-arm study conducted at three Institutes of Central Council for Research in Ayurvedic Sciences. One hundred fifteen women aged between 40 and 55 years with Kupperman menopausal index score ≥15, follicle-stimulating hormone ≥20 IU/L, and endometrial thickness ≤5 mm were included in the study. Three Ayurvedic classical formulations, viz., Ashokarishta, Ashvagandha Churna and Pravala Pishti, were administered for 12 weeks followed by subsequent 2 weeks without intervention follow-up. Outcome measures were changes in menopausal symptoms using menopause rating scale (MRS) and improvement in the quality of life using menopause-specific quality of life (MENQOL) questionnaire and they were assessed at the baseline, 84th day, and at the end of 2 weeks after the completion of intervention period. Paired sample t-test was used to compare mean change from baseline to 84th day. A p-value <0.05 was considered significant.

Results

The findings of the study reveal that the effect of therapy has shown statistically significant decrease in MRS total score (p-value <0.001). The mean MRS total score at the baseline was 22.43 and decreased to 5.29 after treatment at 84th day, and further reduced to 5.06 at the 14th week (follow-up period without trial interventions). The improvements of MENQOL in four domains, viz., vasomotor, psychosocial, sexual, and physical, at the end of 12th week and 14th week were also significant (p-value <0.001) in comparison with the baseline. Further, all the safety parameters like liver function tests and kidney function tests remained within the normal limits throughout the trial period and no adverse events or adverse drug reaction were reported, which confirm the clinical safety of the trial drugs.

Conclusion

Ashokarishta, Ashvagandha Churna and Pravala Pishti are found to be safe and effective in the management of menopausal syndrome.

How to cite this article

Tomar R, Sharma S, Kumari I, Gangurde V, Ota S, Dua P, Khanduri S, Yadav B, Rana R, Singhal R, Srikanth N, Padhi MM, Dhiman KS. Clinical Efficacy and Safety of Ashokarishta, Ashvagandha Churna and Pravala Pishti in the Management of Menopausal Syndrome: A Prospective Open-label Multicenter Study. J Res Ayurvedic Sci 2017;1(1):9-16.


PDF Share
  1. The menopausal age and associated factors in Gorgan, Iran. Med J Islam Repub Iran 2013 May;27(2):50-56.
  2. A psycho-educational program for improving women's attitudes and coping with menopause symptoms. J Obstet Gynecol Neonatal Nurs 2005 Mar-Apr;34(2):233-240.
  3. An evaluation of the contents and quality of menopause information on the World Wide Web. Maturitas 2004 Dec;49(4):276-282.
  4. Combined nutraceutical approach to postmenopausal syndrome and vascular remodeling biomarkers. J Alter Complement Med 2013 Jun;19(6):582-587.
  5. ; editor. Maharshi Sushrut, Sushruta Samhita, Sutra Sthana, Shonitavarnaniya Adhyaya, 14/6. 2nd ed. Varanasi: Chaukhamba Samskrit Samsthan; 2006. p. 48.
  6. Asthanga Hridaya, Sharira Sthana, 1/7. Commentary by Kaviraj Atridev Gupta, Reprinted. Varanasi: Chaukhamba Surbharti Prakashan; 2007. p. 170.
  7. Bhavaprakasha, PurvaKhanda 3/1. In: Mishra PSBS, editor. 9th ed, Varanasi: Chaukhamba Samskrit Samsthana; 2005. p. 204.
  8. An assessment of Manasika Bhavas in menopausal syndrome and its management. Ayu 2010 Jul;31(3):311-318.
  9. Nighantu Adarsha (Purvardha). 1st ed. Varanasi: Chaukhamba Vidya Bhawan; 2013. p. 484.
  10. Ayurvedic formulary of India. Part-I, 2nd ed. New Delhi: Department of AYUSH, Ministry of Health and family welfare, Government of India; 2003. p. 8.
  11. Ayurvedic pharmacopeia of India. Part-I, Vol-I. 1st ed. New Delhi: Department of AYUSH, Ministry of Health and family welfare, Government of India; 2001. p. 19-20.
  12. A comparative pharmaceutico clinical study of Praval Pishti and Praval Bhasma in special reference of management of Hyperacidity. MD thesis. Jamnagar: Rasa Shastra and Bhaishajya Kalpna Department, IPGT and RA; 2003.
  13. The Ayurvedic Pharmacopoeia of India. Part II, Vol I. 1st ed. New Delhi: Department of AYUSH, Ministry of Health and Family Welfare, Government of India; 2007. p. 136-161.
  14. The effects of oxidative stress of female reproduction: a review. Reprod Biol Endocrinol 2012 Jun;10:49.
  15. Oxidative stress and antioxidants: exposure and impact on female infertility. Hum Reprod Update 2008 Jul-Aug;14(4):345-357.
  16. Anti-stressor effect of Withania somnifera. J Ethnopharmacol 1999 Jan;64(1):91-93.
  17. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med 2011 Jul;8(5 Suppl):208-213.
  18. Anti-stress agents (herbs) of Indian origin - herbal drugs, a twenty first century perspective. Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization (DRDO), Govt. of India, Delhi; 2006. pp. 578-591.
  19. Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther 2013 Jul;12(4):312-322.
  20. Anti-inflammatory activity of Withania somnifera leaf extract in stainless steel implant induced inflammation in adult zebrafish. J Genet Eng Biotechnol 2014 Jun;12(1):1-6.
  21. Review of biological activity of withanolides. J Sci Ind Res 1987;46:488-491.
  22. Therapeutic uses of Withania somnifera (Ashwagandha) with a note on withanolides and its pharmacological actions. Asian J Pharm Clin Res 2011 Jul;4(Suppl 1):1-4.
  23. Antioxidant assessment of Ashokarishta – a fermented polyherbal ayurvedic formulation. J Pharm Res 2012 Jun;5(6):3165-3168.
  24. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 2011 Mar;96(3):746-754.
  25. Clinical evaluation of Ashokarishta, Ashwagandha Churna and Praval Pishti in the management of menopausal syndrome. Ayu 2012 Oct;33(4):511-516.
PDF Share